Since the approval of the first antibody-drug conjugate (ADC) drug in 2011, ADC therapeutics have emerged as a promising drug modality. However, due to their novelty and complexity, ADCs pose more technical challenges and unknown consequences for drug developers compared to many conventional drugs. Therefore, ADCs require in vitro metabolism evaluation systems that differ from traditional testing methods. In this webinar, we will share our strategies for tackling these metabolism challenges and accelerating ADC drug development.Specifically, we will focus on overcoming the challenges of ADC development associated with in vitro systems, LC-HRMS methods, and the release and metabolism of payload. By addressing these challenges, we hope to facilitate the efficient and safe development of ADC therapeutics.
Join this webinar to learn
Dr. Guoxiang Huang